Sebastian Nijman, Chief Scientific Officer, Scenic Biotech, explains why harnessing genetic modifiers holds great potential to address the present drug target vacuum and why every drug developer should care about them. According to the National Institute of Health (NIH), approximately 500 of the many thousands of human diseases have an approved treatment. This disappointing result is […]